微管蛋白β(TUBb)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Tubulin Beta (TUBb)
TUB-B; TUBB5; TUBB1; M40
- 編號(hào)SEB870Mi
- 物種Homo sapiens (Human，人), Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3h
- 檢測(cè)范圍0.312-20ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.112ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載英文說(shuō)明書 中文說(shuō)明書
- 規(guī)格48T96T96T*596T*1096T*100
- 價(jià)格¥ 2873¥ 4104¥ 18468¥ 34884¥ 287280
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
實(shí)驗(yàn)結(jié)果圖
標(biāo)準(zhǔn)曲線圖
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒對(duì)檢測(cè)微管蛋白β(TUBb)具有較高的靈敏度。
經(jīng)檢測(cè)人、小鼠、大鼠之間有100%的交叉反映。
回收率
分別于定值血清及血漿樣本中加入一定量的微管蛋白β(TUBb)（加標(biāo)樣品），重復(fù)測(cè)定并計(jì)算其均值，回收率為測(cè)定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 95-103 | 99 |
| EDTA plasma(n=5) | 99-105 | 102 |
| heparin plasma(n=5) | 86-93 | 89 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定，每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的微管蛋白β(TUBb)，并倍比稀釋成1:2，1:4，1:8，1:16的待測(cè)樣本，線性范圍即為稀釋后樣本中微管蛋白β(TUBb)含量的測(cè)定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 79-104% | 78-105% | 95-105% | 85-93% |
| EDTA plasma(n=5) | 91-105% | 96-104% | 99-105% | 93-101% |
| heparin plasma(n=5) | 79-101% | 97-105% | 88-95% | 79-90% |
穩(wěn)定性
經(jīng)測(cè)定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來(lái)進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時(shí)；
3. 吸棄，加檢測(cè)溶液A100µL，37°C孵育1小時(shí)；
4. 洗板3次；
5. 加檢測(cè)溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將微管蛋白β(TUBb)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的微管蛋白β(TUBb)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的微管蛋白β(TUBb)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過(guò)氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的微管蛋白β(TUBb)呈正相關(guān)。用酶標(biāo)儀在450nm波長(zhǎng)下測(cè)定吸光度(O.D.值)，計(jì)算樣品濃度。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人), Mus musculus (Mouse，小鼠), Rattus norvegicus (Rat，大鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| CAB870Mi01 | 抗微管蛋白β(TUBb)多克隆抗體 | Loading Control of WB. |
| CAB870Mi22 | 抗微管蛋白β(TUBb)單克隆抗體 | Loading Control of WB |
| SEB870Mi | 微管蛋白β(TUBb)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB870Mi | 微管蛋白β(TUBb)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| archives of pharmacal research | Synthesis and cytotoxic activity of certain trisubstituted azetidin-2-one derivatives as a cis-restricted combretastatin A-4 analogues[pubmed:27747473] |
| archiv der pharmazie (Weinheim). | New 3-Substituted-2-(4-hydroxyanilino)pyridine Derivatives: Synthesis, Antitumor Activity, and Tubulin Polymerization Inhibition.[pubmed:28150327] |
| ACS?Applied?Materials?&?Interfaces | Novel Beta-Tubulin-Immobilized Nanoparticles Affinity Material for Screening β-Tubulin Inhibitors from a Complex Mixture[pubmed:28112513] |
| Future?Medicinal Chemistry | Design, synthesis and biological evaluation of chromenopyrimidines as potential cytotoxic agents[Pubmed:29779400] |
| Future?Medicinal Chemistry | Design and synthesis of novel 5-(4-chlorophenyl) furan derivatives with inhibitory activity on tubulin polymerization[Pubmed:29966433] |
| Journal of Biological Chemistry | Biochemical characterization of the PHARC associated serine hydrolase ABHD12 reveals its preference for very long chain lipids[Pubmed: 30237167] |
| Journal?of?Enzyme?Inhibition?and?Medicinal?Chemistry | Design, synthesis, and screening of amino thiophene carboxamide derivatives on hepatocellular carcinomaas VEGFR-2Inhibitors[Pubmed: 30191744] |
| European Journal of Medicinal Chemistry | Potent combretastatin A-4 analogs containing 1, 2, 4-triazole: Synthesis, antiproliferative, anti-tubulin activity, and docking study[Pubmed: 31536891] |
| ACS Sensors | Early diagnosis of Alzheimer's disease in blood using a disposable electrochemical microfluidic platform[Pubmed: 32207606] |
| Bioorganic Chemistry | Tubulin Inhibitors: Discovery of a New Scaffold Targeting Extra-binding Residues within the Colchicine Site through Anchoring Substituents Properly Adapted to their?…[Pubmed: 32325332] |
| BRITISH JOURNAL OF NUTRITION | Ginger and turmeric lipid-solubles attenuate heated oil-induced cardio-hepatic oxidative stress via the upregulation of NRF2 and decrease blood pressure in rats[Pubmed: 33028437] |
| European Journal of Medicinal Chemistry | Design, Synthesis and Screening of Benzimidazole Containing Compounds with Methoxylated Aryl Radicals as Cytotoxic Molecules on (HCT-116) Colon?…[Pubmed: 33158579] |
| J BIOMOL STRUCT DYN/JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS | Cytotoxicity, in silico predictions and molecular studies for androstane heterocycle compounds revealed potential antitumor agent against lung cancer cells[33300466] |
| Cancer Cell International | Bufalin Induced Mitochondrial Dysfunction Promotes Apoptosis of Glioma Cells by Regulating Annexin A2 and DRP1 Proteins[] |
| Cancer Cell Int | Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression[34376212] |
| Sci Rep | Curcumin derivative ST09 modulates the miR-199a-5p/DDR1 axis and regulates proliferation and migration in ovarian cancer cells[34837026] |
